ProQR Therapeutics has spun out its early-phase oligonucleotide treatment for a rare inherited skin disorder to form a new company. The spinout, Wings Therapeutics, starts life with a phase 1/2 asset and funding from a disease-focused nonprofit.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,